Intranasal mechanical stimulation
The talk page may contain suggestions.
Theory[edit | edit source]
Evidence in ME/CFS[edit | edit source]
A small placebo-controlled randomized clinical trial by Rodriguez et al. (2020) of moderate and severe patients with ME/CFS found that a 30% reduction in symptoms was achieved after 8 weeks of INMEST treatment; however the fatigue level of patients did not change. The trial used patients who fulfilled the Canadian Consensus Criteria. Dr Jan-Erik Juto, one of the authors of Rodriguez et al. (2020), is a co-founder and stakeholder of Albilion Medical Systems AB, who developed INMEST.
Clinicians[edit | edit source]
Risks and safety[edit | edit source]
Costs and availability[edit | edit source]
See also[edit | edit source]
Learn more[edit | edit source]
- Intranasal Mechanical Stimulation - Albilion Medical Systems AB
References[edit | edit source]
- Rodriguez, Lucie ST; Pou, Christian; Tadepally, Lakshmikanth; Zhang, Jingdian; Mugabo, Constantin Habimana; Wang, Jun; et al. (February 21, 2020). "Achieving symptom relief in patients with Myalgic encephalomyelitis by targeting the neuro-immune interface and inducing disease tolerance" (PDF). bioRxiv: 2020.02.20.958249. doi:10.1101/2020.02.20.958249. Retrieved February 25, 2020.